Market Research Logo

Ajanta Pharma Ltd (AJANTPHARM) - Financial and Strategic SWOT Analysis Review

Ajanta Pharma Ltd (AJANTPHARM) - Financial and Strategic SWOT Analysis Review - provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Ajanta Pharma Ltd (Ajanta Pharma) is a specialty pharmaceutical company, which focuses on the research, manufacture and commercialization of finished dosages in domestic and international markets. The company has a presence in cardiology, pain management, dermatology and ophthalmology therapy areas. It provides generics in developed markets of USA and branded generics in emerging countries such as India, Africa, CIS, Middle East and South East Asia. Ajanta Pharma also supplies multivitamins, eye drops, cough syrups and antibiotics to government bodies in India; and anti-malarial products to Africa and Global Fund. It operates subsidiaries in Mauritius, Philippines, Nigeria, the US and the UK. Ajanta Pharma is headquartered in Mumbai, Maharashtra, India.

Ajanta Pharma Ltd Key Recent Developments

Jul 31,2018: Ajanta Pharma reports Q1 FY 2019 consolidated result
Jul 27,2018: Ajanta Pharma: Update on US FDA inspection
Jul 13,2018: National drug regulator finds illegal manufacturing at Pondy firm
May 02,2018: Ajanta Pharma reports Q4 FY 2018 Consolidated Result
Jan 25,2018: Ajanta Pharma: Q3 Income from Operations at Rs. 587 cr., PAT at Rs. 147 cr.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Ajanta Pharma Ltd - Key Facts
Ajanta Pharma Ltd - Key Employees
Ajanta Pharma Ltd - Key Employee Biographies
Ajanta Pharma Ltd - Major Products and Services
Ajanta Pharma Ltd - History
Ajanta Pharma Ltd - Company Statement
Ajanta Pharma Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Ajanta Pharma Ltd - Business Description
Ajanta Pharma Ltd - Corporate Strategy
Ajanta Pharma Ltd - SWOT Analysis
SWOT Analysis - Overview
Ajanta Pharma Ltd - Strengths
Ajanta Pharma Ltd - Weaknesses
Ajanta Pharma Ltd - Opportunities
Ajanta Pharma Ltd - Threats
Ajanta Pharma Ltd - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Ajanta Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Ajanta Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Ajanta Pharma Ltd, Recent Deals Summary
Section 5 – Company’s Recent Developments
Jul 31, 2018: Ajanta Pharma reports Q1 FY 2019 consolidated result
Jul 27, 2018: Ajanta Pharma: Update on US FDA inspection
May 02, 2018: Ajanta Pharma reports Q4 FY 2018 Consolidated Result
Jan 25, 2018: Ajanta Pharma: Q3 Income from Operations at Rs. 587 cr., PAT at Rs. 147 cr.
Jan 25, 2018: Ajanta Pharma reports Q3 FY 2018 Consolidated Result
Dec 15, 2017: Ajanta Pharma: Change in designation of a Director
Aug 09, 2017: Ajanta Pharma: Income from Operations at Rs. 473 cr., PAT at Rs. 95 cr
Apr 10, 2017: Ajanta Pharma Provides Update On US FDA Inspection At Dahej Formulation Facility
Feb 09, 2017: Ajanta Pharma Provides Update On US FDA Inspection
Jan 24, 2017: Ajanta Pharma Announces No import alert on us by US FDA
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tabless
Ajanta Pharma Ltd, Key Facts
Ajanta Pharma Ltd, Key Employees
Ajanta Pharma Ltd, Key Employee Biographies
Ajanta Pharma Ltd, Major Products and Services
Ajanta Pharma Ltd, History
Ajanta Pharma Ltd, Subsidiaries
Ajanta Pharma Ltd, Key Competitors
Ajanta Pharma Ltd, Ratios based on current share price
Ajanta Pharma Ltd, Annual Ratios
Ajanta Pharma Ltd, Annual Ratios (Cont...1)
Ajanta Pharma Ltd, Annual Ratios (Cont...2)
Ajanta Pharma Ltd, Interim Ratios
Ajanta Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Ajanta Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Ajanta Pharma Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Ajanta Pharma Ltd, Performance Chart (2014 - 2018)
Ajanta Pharma Ltd, Ratio Charts
Ajanta Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Ajanta Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report